MAP2K7 and glioblastoma: Our results further confirmed that AZD-9291 and GDC-0084 combination therapy simultaneously inhibited the MEK/ERK and AKT/mTOR signaling pathways downstream of EGFR, thereby inhibiting the growth of primary GBM cells.